Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025241 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
A Phase 2 study, sponsored by Neuren Pharmaceuticals Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT05025241 is a Phase 2 study that has completed, run by Neuren Pharmaceuticals Limited. The registered enrollment target is 18 participants.
The verdict
NCT05025241, a Phase 2 study, has completed, sponsored by Neuren Pharmaceuticals Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Phelan-McDermid Syndrome.
Interventions
- DRUG NNZ-2591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05025241
The ClinicalTrials.gov registry entry for NCT05025241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuren Pharmaceuticals Limited, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NNZ-2591 is the first listed.
NCT05025241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05025241 about?
NCT05025241 is a clinical study titled "An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)". A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Phelan-McDermid Syndrome.
What is the current status of trial NCT05025241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-08-08. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT05025241?
The interventions under investigation include: NNZ-2591 (DRUG).
Who is sponsoring clinical trial NCT05025241?
This trial is sponsored by Neuren Pharmaceuticals Limited, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.